Penumbra, Inc. (NYSE:PEN) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Bob Hopkins - Bank of America Lawrence Biegelsen - Wells Fargo William Plovanic - Canaccord Robbie Marcus - JPMorgan Joanne Wuensch - Citigroup Margaret Kaczor - William Blair Operator Good aftern ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Penumbra, Inc. (NYSE:PEN) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Stephen Dobson - Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Brandon Vazquez - William Blair Bob Hopkins - Bank of America Operator Good afternoon. My name is Katrina, and I will be your conference operator tod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2020 were $166.9 million, a year-over-year increase of 14.9% as reported and 13.7% in constant currency, marking the second consecutive record quarter for the company [10] - For the full year 2020, total annual revenues were $560.4 million, representing growth of 2.4% over 2019 [11] - Non-GAAP revenue for Q4 2020 grew 18.9% to $172.7 million, excluding a one-time impact from a product recall [10][11] - Non-GAAP gross margin for Q4 2020 was 65.2%, down from 67.6% a year ago, but improved sequentially from 16.2% in Q3 2020 [47] Business Line Data and Key Metrics Changes - Revenue from the vascular business grew to $87.1 million in Q4 2020, an increase of 45.5% reported compared to the same period last year [44] - Revenue from the neuro business was $85.6 million in Q4 2020, a slight increase of 0.2% reported, but a decrease of 1.2% in constant currency [45] - The vascular franchise became the largest business for the first time in Q4 2020, driven by strong growth in vascular thrombectomy and embolization products [15][20] Market Data and Key Metrics Changes - The geographic mix of sales in Q4 2020 was 70% US and 30% International, with US and international reported sequential growth of 10.5% and 24.4% respectively compared to Q3 2020 [43] - The international neuro business increased by 30.3% sequentially and 5% reported compared to the same quarter a year ago, driven by strong performance across Europe, China, and Asia-Pacific regions [46] Company Strategy and Development Direction - The company is focused on innovation and has a broad portfolio of products aimed at addressing significant healthcare challenges [12][13] - The company is optimistic about future growth opportunities in international markets, particularly in China and Japan, despite challenges faced in 2020 [31][34] - The company aims to introduce new products that could change the paradigm in stroke intervention, focusing on removing all clot as quickly as possible [96] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the COVID-19 pandemic but expressed confidence in the company's ability to navigate production capacity and meet demand [36][37] - The company expects revenue guidance for full-year 2021 in the range of $675 million to $685 million, representing 20% to 22% growth over full-year 2020 [55] - Management remains optimistic about the recovery of the stroke market and the potential for growth in vascular and neuro businesses [25][34] Other Important Information - The voluntary recall of Jet 7 Xtra Flex had a financial impact of $5.8 million in revenue and $12.6 million in charges to costs of sales in Q4 2020 [40] - The company ended the year with $265 million in cash and cash equivalents and no debt, indicating a strong balance sheet [53] Q&A Session Summary Question: Concerns about 2021 guidance being below Q4 2020 annualized results - Management explained that the guidance reflects the impact of COVID-19 and the recall of Jet 7 Xtra Flex, but they remain optimistic about sequential growth throughout the year [66][67] Question: Features and timing of new neurovascular platform - Management refrained from providing specific details but indicated that updates to reperfusion catheters are aimed at improving performance [70] Question: Impact of Lightning products on vascular business - Management highlighted the larger patient population for arterial treatments and expressed confidence in the positive long-term impact of Lightning products [74] Question: Updates on REAL product and its contribution to revenue - Management stated that 2021 will focus on laying the groundwork for future revenue growth from REAL, rather than expecting significant contributions this year [82] Question: Impact of COVID-19 on vascular business - Management noted that while there was an initial increase in patients with clots due to COVID-19, the overall quantifiable impact is not significant [103] Question: Future growth expectations and confidence in reaching $1 billion revenue - Management expressed confidence based on recent growth trends and the potential of their product portfolio to address significant healthcare needs [90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-37557 Penumbra, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporatio ...

Penumbra, Inc. (NYSE:PEN) Q3 2020 Results Earnings Conference Call October 28, 2020 4:30 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - President, Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Bill Plovanic - Canaccord Robbie Marcus - JP Morgan Bob Hopkins - Bank of America Merrill Lynch Joanne Wuensch - Citigroup Margaret Kaczor - William Blair Ryan Zimmerman - BTIG Operator Good after ...

Penumbra, Inc. (NYSE:PEN) Q2 2020 Earnings Conference Call August 3, 2020 4:30 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Conference Call Participants Bob Hopkins - Bank of America Cecilia Furlong - Canaccord Genuity Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Joanne Wuensch - BMO Capital Markets Operator Good afternoon. My name is Sidarius, and I will be your conference operator toda ...

Penumbra, Inc. (NYSE:PEN) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Sri Kosaraju - President Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Matt Henriksson - Citi Malgorzata Kaczor - William Blair Operator Good afternoon. My name is Lee, and I will be your conference operator today. At this time, I would like t ...

Penumbra, Inc. (NYSE:PEN) Q4 2019 Earnings Conference Call February 25, 2020 5:00 PM ET Company Participants Jee Hamlyn-Harris - IR Adam Elsesser - Chairman and CEO Maggie Yuen - CFO Sri Kosaraju - President Conference Call Participants Jason Mills - Canaccord Genuity Robbie Marcus - JPMorgan Bob Hopkins - Bank of America Larry Biegelsen - Wells Fargo Operator [Starts Abruptly] Fourth Quarter and Year-End 2019. A copy of the press release and financial tables, which includes the GAAP to non-GAAP reconciliat ...